Vorapaxar
Vorapaxar Basic information
- Product Name:
- Vorapaxar
- Synonyms:
-
- Vorapaxar
- Vorapaxar (SCH 530348)
- [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-carbamic acid ethyl ester
- Voarapaxar
- Ethyl [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]vinyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamate
- [(1R,3AR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-me
- Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester
- CS-1663
- CAS:
- 618385-01-6
- MF:
- C29H33FN2O4
- MW:
- 492.58
- Product Categories:
-
- API
- Mol File:
- 618385-01-6.mol
Vorapaxar Chemical Properties
- Boiling point:
- 676.0±55.0 °C(Predicted)
- Density
- 1.24±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20° C
- solubility
- ≥24.65 mg/mL in DMSO; insoluble in H2O; ≥10.64 mg/mL in EtOH with ultrasonic
- form
- solid
- pka
- 12.49±0.60(Predicted)
- color
- White to off-white
Vorapaxar Usage And Synthesis
Description
Vorapaxar is an orally bioavailable competitive antagonist of the proteinase-activated receptor (PAR1; Ki = 8.1 nM), also known as the thrombin receptor. It is selective for PAR1 over other PARs, as well as a number of GPCRs, ion channels, and receptors. It inhibits platelet aggregation induced by thrombin and haTRAP (IC50s = 47 and 25 nM, respectively). Vorapaxar (0.1 mg/kg, i.v.) completely inhibits platelet aggregation in cynomolgus monkeys ex vivo. Formulations containing vorapaxar are used in the prevention of thrombotic cardiovascular events.
Definition
ChEBI: A carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethyny }-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation.
References
[1]. chackalamannil s & xia, y. thrombin receptor (par-1) antagonists as novel antithrombotic agents. expert opinion on therapeutic patents, 2006.16:493-505.
[2]. chackalamannil s, wang y, greenlee w j et al. 2008. discovery of a novel, orally active himbacine-based thrombin receptor antagonist (sch 530348) with potent antiplatelet activity. j med chem, 2008,51: 3061-3064.
VorapaxarSupplier
- Tel
- 010-56645598 13366904824
- bjkaida@163.com
- Tel
- 021-50790412
- info@chemvon.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Tel
- 021-61551611 13296011611
- contact@trustwe.com
Vorapaxar(618385-01-6)Related Product Information
- vorapaxar sulfate M-9
- GS9857
- Voreloxin
- PVM/MA
- Panipenem
- Pazopanib
- LCZ696
- RANAKININ
- Cilostazol
- (3R,3aS,4S,4aS,7R,9aR)-3-Methyl-7-nitro-1-oxo-N,N-diphenyl-1,3,3a,4,4a,5,6,7,8,9a-decahydronaphtho[2,3-c]furan-4-carboxamide
- Vorapaxar Sulfate
- Vorapaxar
- (1R,3aR,4aR,8aR,9S,9aR)-1-methyl-3-oxodecahydro-3H-spiro[naphtho[2,3-c]furan-6,2'-[1,3]dioxolane]-9-carboxylic acid